Production (Stage)
Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 41.31% | 65.39% | -3.28% | -143.26% | 578.64% |
| Total Depreciation and Amortization | 103.36% | -3,196.00% | -3.85% | -96.40% | -- |
| Total Amortization of Deferred Charges | -98.55% | 4,161.90% | -8.70% | 15.00% | -71.43% |
| Total Other Non-Cash Items | 159.76% | -94.59% | 369.62% | -16.88% | 809.09% |
| Change in Net Operating Assets | -7,926.92% | 101.88% | 34.42% | -117.65% | 1,084.61% |
| Cash from Operations | -192.94% | 33.18% | 73.70% | -121.48% | 903.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -53.45% | -- | -- | -44.66% | -16.06% |
| Repurchase of Common Stock | -33.33% | 98.30% | -486.67% | -373.68% | -11.76% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | 102.94% | -2,212.88% | -305.45% | 122.70% | -119.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.07% | -400.59% | 66.37% | -121.44% | 4,258.05% |